Increasing number of studies have shown nuclear localization of the insulin-like growth factor 1 receptor (nIGF-1R) in tumor cells and its links to adverse clinical outcome in various cancers. Any obvious cell physiological roles of nIGF-1R have, however, still not been disclosed. Previously, we reported that IGF-1R translocates to cell nucleus and modulates gene expression by binding to enhancers, provided that the receptor is SUMOylated. In this study, we constructed stable transfectants of wild type IGF1R (WT) and triple-SUMO-site-mutated IGF1R (TSM) using igf1r knockout mouse fibroblasts (R-). Cell clones (R-WT and R-TSM) expressing equal amounts of IGF-1R were selected for experiments. Phosphorylation of IGF-1R, Akt, and Erk upon IGF-1 stimulation was equal in R-WT and R-TSM. WT was confirmed to enter nuclei. TSM did also undergo nuclear translocation, although to a lesser extent. This may be explained by that TSM heterodimerizes with insulin receptor, which is known to translocate to cell nuclei. R-WT proliferated substantially faster than R-TSM, which did not differ significantly from the empty vector control. Upon IGF-1 stimulation G1-S-phase progression of R-WT increased from 12 to 38%, compared to 13 to 20% of R-TSM. The G1-S progression of R-WT correlated with increased expression of cyclin D1, A, and CDK2, as well as downregulation of p27. This suggests that SUMO-IGF-1R affects upstream mechanisms that control and coordinate expression of cell cycle regulators. Further studies to identify such SUMO-IGF-1R dependent mechanisms seem important.
regulatory effects while retaining IGF-1R kinase-dependent signaling (Sehat et al., 2010) .
Since our discovery and first characterization of nIGF-1R, several new aspects on it have been reported. nIGF-1R has been linked to adverse patient outcome or tumor progression in renal cell carcinomas, embryonal rhabdomyosarcomas, and synovial sarcomas (Aleksic et al., 2010; Palmerini et al., 2015; van Gaal et al., 2013) . It has been proposed as a marker of overall survival and progression-free survival in patients with soft tissue sarcomas and osteosarcomas treated with anti-IGF-1R antibody therapy (Asmane et al., 2012) . High levels of nIGF-1R has also been reported in several cancer cell lines, including human alveolar rhabdomyosarcoma, hepatocellular, prostate, and breast carcinoma, as well as acute myeloid leukemia cells (Aslam et al., 2013; Chein, Kuo, Liao, Wang, & Yu, 2016; Deng et al., 2011; Sarfstein et al., 2012; Zhang et al., 2015) .
As SUMO1 modification is critical for IGF-1R's transactivating effects and nuclear receptor is linked to adverse clinical outcome and tumor biological properties, we, here, sought to investigate whether the SUMOylation status of IGF1R may affect cell proliferation. For this purpose, we established a model system using igf1r−/− knockout murine embryonic fibroblast transfected with either wild type IGF1R or IGF1R with mutated SUMOylation sites.
| MATERIAL AND METHODS

| Cell lines and reagents
The igf1r deficient R-cell line was isolated from mouse embryos with a targeted disruption of the igf1r gene by Dr. Renato Baserga's group (Sell et al., 1993) . pBABE-Puro retroviral expression vector (#RTV-001-PURO) and Platium-E packaging cell line (#RV-101) were bought from Cell Biolabs Inc. (San Diego, CA).
Agar (#214220), BrdU (#550891), 7-AAD (#559925), mouse anti-IGF1R (#556000), and FITC labeled mouse anti-BrdU (#347583) was purchased from Becton, Dickinson and Company (San Jose, CA).
Polybrene (sc-134220), antibodies against GAPDH (sc-25778), cyclin A (SC-751), cyclin D (SC-450), cyclin E (SC-247), CDK2 (SC-748), and normal mouse IgG (sc-2025) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). IGF-1R (#3027), pAkt (#9275), pErk (#9101), SUMO-1 (#4940), CDK4 (#2906), p27 kip1 (#3698), InsR β (#3020), and phospho-tyrosine (#9411) antibodies were purchased from Cell Signaling Technology (Danvers, MA). Cyclin B1 (ab181593) and CDK1 (ab18) antibodies were provided by Abcam (Cambridge, MA).
qRT-PCR primers for IGF1R (#Hs00609566_m1) and GAPDH (#Mm99999915_g1), puromycin (#A11138), and protein G Dynabeads (#10004D) were provided by Life Technologies (Carlsbad, CA).
| Retrovirus production
Wild type (WT) and triple-SUMO1-site-mutated (TSM) IGF1R expression sequences were PCR amplified from vectors previously generated in our group (Sehat et al., 2010) and sub-cloned into pBABE-puro vector. After sequencing confirmation, the pBABE-puro, pBABE-WT, and pBABE-TSM vectors were transfected into Platium-E cell line respectively. At 48 and 72 hr post transfection, the supernatants with packaged retrovirus particles were collected and filtered through 0.45 μm polysulfonic filters before infecting R-cells.
| Knock-in of WT/TSM-IGF1RWT/TSM-IGF1R
The R cells were seeded in 25 cm 2 flasks at 30% confluency in complete DMEM medium. For infection, 5 ml retrovirus supernatants with 8 μg/ml polybrene were added to each flask at 24, 48, and 72 hr post seeding. pBABE-puro, pBABE-WT, and pBABE-TSM retrovirus particles were employed for mock, WT-IGF1R, and TSM-IGF1R transfection, respectively. Four days after seeding, 1 μg/ml puromycin was supplemented in to the culture medium to eliminate untransfected cells. Mediums were changed every third day until the cells were 90% confluent.
| Generation of monoclonal cell lines
Transfected R-cells were diluted to 10 viable cells per ml medium and 0.1 ml was dispensed to each well in 96-well cell culture plates. After 10 days' incubation at 37°C, wells with single clone were isolated and expanded. qRT-PCR was applied to determine the relative IGF1R expression level in each clone, using a delta-delta Ct protocol and GAPDH as endogenous control.
| Immunoprecipitation (IP)
For each cell line, 10 7 cells were harvested and boiled in 100 µl TSD buffer (50 mM Tris-Cl, 1% SDS, 5 mM DTT, 20 mM N-Ethylmaleimide, and 1× protease and phosphatase inhibitor) for 10 min, followed by brief sonication and centrifugation at 16,000 g for 10 min. The supernatants were diluted with 1.2 ml of TNN buffer (50 mM Tris-Cl, 250 mM NaCl, 5 mM EDTA, 0.5% NP-40, 20 mM N-Ethylmaleimide, and 1×protease and phosphatase inhibitor).
IGF-1R was pull down with 5 µl mouse anti-IGF1R antibody and 10 µl protein G Dynabeads overnight at 4°C. Precipitated proteins were separated by SDS-PAGE, transferred onto a nitrocellulose membrane and blotted with specific antibodies.
| XTT cell proliferation assay
In a 96-well plate, 3 × 10 3 of R-puro, R-WT, R-TSM, WT-2D5, or actinomycin D (7-AAD) was used to stain the DNA. Cells in G0/G1, S, and G2/M phases were gated using an ACEA NovoCyte™ 3000 flow cytometry with the NovoExpress™ software based on their BrdU and 7-AAD content. R-puro, R-WT, or R-TSM cells were cultured under basal condition at 70% confluency. Apoptosis was studied using Annexin V/PI method (Annexin V-FLUOS staining kit, Roche, Mannheim, Germany) according to the manufacturer's protocol.
Flow cytometric analysis was immediately performed using the NovoCyte™ 3000.
| Soft agar colony formation assay
Six-well plates were precast with 2 ml DMEM medium supplemented with 10% FBS and 0.5% agar as the bottom layer. R-puro, R-WT, and 3 | RESULTS
| Cell line verification and characterization
The different igf1r−/− knockout cell clones transfected with WT or TSM IGF1R expressed variable mRNA levels of IGF1R as determined by qRT-PCR (Fig. 1A) . WT-2C4 and TSM-2D4 clones exhibiting equal IGF1R mRNA (Fig. 1A ) and protein levels ( Fig. 1B) were selected for further experiments and were named R-WT and R-TSM, respectively.
The protein levels of IGF1R in R-WT and R-TSM were essentially in the range of those in common cancer cell lines (Fig. 1B) . R-puro (empty vector transfectant) showed no IGF1R mRNA or IGF-1R expression ( Fig. 1A and B) .
SUMOylation of the transfected cell lines was investigated by immunoprecipitation of IGF-1R followed by detection of SUMO1 by immunoblotting. We observed that SUMO-modified IGF-1R was restricted to R-WT cells (Fig. 1C) .
To compare the activity of IGF-1R signaling in the transfected cell lines, phosphorylation of IGF-1R, Akt, and Erk was determined before and after stimulation with 50 ng/ml IGF-1 in serum-starved cells.
Whereas R-puro showed no response (except a faint increase in pAkt that is judged as unspecific) to ligand stimulation, both R-WT and R-TSM showed clear and equal phosphorylation of IGF-1R, Akt, and Erk (Fig. 1D ). This supports that TSM modified IGF-1R has an intact tyrosine kinase activity.
Next, the cell lines were subjected to nuclear extraction. Nuclear TSM-IGF-1R was detectable, but at a much lower level compared to WT-IGF-1R (Fig. 1E) . A possible explanation could be heterodimerization of IGF-1R with insulin receptor (InsR). Accordingly, InsRβ coprecipitated with IGF-1Rβ in both R-WT and R-TSM cell lines (Fig. 1F ).
This was confirmed by PLA, which indicated the co-localization of InsRβ and IGF-1Rβ in all compartments of the cells, including nuclei (Fig. 1G ).
| SUMOylated IGF-1R increases proliferation in R-cells
Cell proliferation was measured daily over five consecutive days using an XTT colorimetric assay. During the whole experimental time R-WT showed a significantly higher proliferation (t-test, p < 0.05 for all time points) than both R-puro and R-TSM ( Fig. 2A) . At the final measure (day 5), R-WT had a 3.6-fold increase in viable cells as compared to R-puro (2.1-fold increase) and R-TSM (2.7-fold increase). R-TSM showed only a minor increase in proliferation as compared to R-puro (significantly higher at days 3 and 5). To verify these results, another set of stable cell clones with equal expression of IGF-1R, WT-2D5, and TSM-3B4 (cf. Fig. 1A) , was compared over a 4-day culturing. Similar to R-WT, WT-2D5 showed a significantly higher proliferation (p < 0.05) than both TSM-3B4 and R-puro (Fig. 2B) .
The apoptotic/cell death rate of the cell lines was assessed by FACS after staining with Annexin V/PI, for detection of early and late apoptosis. As shown in Fig. 2C , the relative numbers of apoptotic cells in the three cell lines were essentially comparable. Staurosporin was used as a positive control.
| SUMO modification of IGF-1R increases G1-S progression
Based on the results on cell proliferation, we investigated the effects of SUMOylation status on cycle progression. The cells lines were synchronized by serum starvation for 36 hr to accumulate most of the cells in G1-phase. After 0, 10, 16, or 24 hr of IGF-1 stimulation the percentages of cells in different cell cycle phases were determined using BrdU/PI double staining, followed by FACS (Fig. 3A) . As shown in Fig. 3B and C, the most substantial changes observed were the increase in S-phase and corresponding decrease in G1-phase in ligand stimulated R-WT. After a 26% increase at 16 hr, the number of S-phase cells was clearly decreased by 24 hr. The corresponding response in R-TSM was much weaker with highest increase (8%) at 24 hr. No significant changes were detected in R-puro cell line ( Fig. 3B and C) .
During the 24 hr experiment, we could not detect any significant changes in G2/M phase in any of the cell lines, although R-WT exhibited a trend of increased G2/M (Fig. 3D) . Probably a substantial portion of IGF-1 stimulated W-RT cells had undergone mitosis before 24 hr, which is in line with the increase in G1 cells at 24 hr (Fig. 3C) . S phase cyclin D1 after 10 hr, which was followed by increase in S phase cyclin A and G2/M cyclin B1 after 16 and 24 hr, respectively (Fig. 4) .
These changes match the cell cycle kinetic events (Fig. 3) . The enhanced expression of cyclin B1 together with the trend for increase in G2/M and G1 at 24 hr suggests that S-G2 progression is fastened in ligand stimulated R-WT cells (Figs. 3, 4) . No detectable changes in cyclin E expression were seen (Fig. 4) . Compared to R-WT, ligand stimulated R-TMS showed weaker increase in cyclin A and B1, and cyclin D1 was only hardly affected (Fig. 4) . The S-phase CDK2 was the only CDK exhibiting a detectable upregulation upon IGF-1 stimulation during the experimental time and it was strongest for R-WT (Fig. 4) . Upon ligand treatment of R-WT, the expression of CIP/KIP p27 was decreased, while it was not affected in R-TSM. No detectable changes in p21 were seen in any of the cell lines (Fig. 4) . Except a small increase in cyclin B1, no changes were observed in R-puro.
Taken together, the cell cycle kinetic data (Fig. 3 ) and changes in cell cycle proteins (Fig. 4) suggest that SUMO modification mainly regulates IGF-1R-dependent cell proliferation through increasing G1-S progression. As several cell cycle proteins were affected, their expression is most likely conducted by upstream events.
| SUMOylated IGF-1R increases anchorage independent cell growth
To investigate the potential role of SUMOylated IGF-1R in anchorage independent growth, the cell lines were analyzed for colony formation using soft agar assay (Fig. 5 ). Cells were cultured in soft agar for 2 weeks. The R-WT cell line formed significantly more colonies than both R-puro and R-TSM (p < 0.05). Significantly increased colony formation was also seen in R-TSM (p < 0.05) compared to R-puro.
Thus, IGF-1R's canonical signaling seems also important for anchorage independent growth.
| DISCUSSION
Nuclear localization of IGF-1R is emerging as a potentially important factor in tumor pathophysiology and clinical prediction.
However, its specific role in a cell physiological context is still poorly understood. Initially, we reported that SUMOylation is important for nuclear IGF-1R-induced transactivation (Sehat et al., 2010) . In this study, we established a cell model (R-WT/ R-TSM) for assessment of cellular responses in cells expressing SUMO-modified IGF-1R versus non-SUMO-modified IGF-1R. We focused on potential effects on cell proliferation and cell cycle progression. We demonstrated that R-WT cells (expressing SUMO-modified receptor) were coupled to a significant increase in cell proliferation mainly through G1-S phase transition as compared to R-TSM cells (expressing non-SUMO-modified receptor). These data provide direct evidence that SUMOylation is important for IGF-1R-induced cell proliferation. In consistence with our finding, Zhang et al. (2015) showed that co-expression of IGF-1R containing SUMOylation site mutations (i.e., K1025R and K1100R) substantially decreased proliferation in acute myeloid leukemia cells. Furthermore, a correlation between estrogen receptor positive breast cancer cells TSM-mutated and wild-type IGF-1R had intact and equal kinase activity as determined by Akt and Erk phosphorylation after IGF1-stimulation. We were, therefore, surprised to observe that R-TSM did not differ much in proliferation and cell cycle progression compared to R-puro (mock transfected cells), suggesting a limited proliferative effect of membranous IGF-1R in this model. Some cell types have previously been described to respond with differentiation rather than proliferation upon IGF-1R stimulation (Baserga, 2009 ). We could confirm that the difference in proliferation rate was not due to difference in rate of apoptotic cell death. While an even starker effect was seen in WT transfected cells, we observed a clear effect of TSM transfection on soft agar colony formation.
Hypothetically, the canonical IGF-1R signaling may affect cell growth predominantly through increasing cell survival (e.g., Baserga, 2009; Resnicoff et al., 1996) , whereas SUMO-dependent signaling mainly affects cell proliferation. The finding that co-expression of IGF-1R K1025R/ K1100R in leukemia cells decreased proliferation but did not cause apoptosis (Zhang et al., 2015) supports this hypothesis.
Under the experimental conditions (basal) applied in the present study, we could not detect any difference in rate of apoptotic cell death in R-WT and R-TSM.
The observation that SUMOylation of IGF-1R is important for cell growth may partly explain the more aggressive phenotype of tumors expressing nuclear IGF-1R. SUMOylated IGF-1R might even be a more accurate biomarker than nuclear IGF-1R in clinical management. For example, in situ proximity ligation assay (PLA) for detection of SUMO-IGF-1R in tumor specimen may become a feasible method in this respect.
FIGURE 4
Comparison of expression of cell cycle proteins. R-puro, R-WT, and R-TSM were synchronized by 36 hr serum starvation and then exposed to 50 ng/ml IGF-1 for 0, 10, 16, and 24 hr. Protein expression of cyclin A, cyclin B1, cyclin D1, cyclin E, CDK1, CDK2, CDK4, p21, and p27 was detected by immunoblotting. Tubulin was blotted as loading control. Data are representative of >3 experiments The mechanism underlying the ability of SUMOylated IGF-1R to induce proliferation and cell cycle progression remain requires further studies. In the current study, we found increased expression of cyclin D1, cyclin A, and CDK2 as well as decrease in p27 in R-WT cells, events that are known to drive cells from G1-to and through the S-phase. As several cell cycle regulators are involved, upstream mechanisms most likely control and coordinate their expression. Such mechanisms might be dependent on the SUMOylation status of IGF-1R. We, previously,
showed that nIGF-1R binds to enhancer-like regions and that WT-IGF-1R increased reporter gene activity if these regions were inserted in the reporter vector (Sehat et al., 2010) . In contrast, TSM-IGF-1R inhibited the gene activity. These data suggest that
SUMOylation is important for nIGF-1R-induced transactivation. This could depend on that SUMO-modification regulates nuclear import of IGF-1R but also that SUMO1-IGF-1R may directly influence the transactivation process, for example, by binding to enhancers (Sehat et al., 2010) or to transcription factors (Warsito et al., 2012) or by interfering with epigenetic mechanisms (Warsito et al., 2016) .
In the present study, we show that TSM-IGF-1R also can translocate to the cell nucleus, but to a much lower extent compared to WT-IGF-1R. This suggests that SUMOylation of IGF-1R is not an absolute requirement for nuclear translocation. Alternatively, TSM could be transported to the cell nucleus through heterodimerizing with the InsR. Actually, we could show that IGF-1R co-localizes with InsR in MEFs. Irrespective of which, the biological response (i.e., cell proliferation) is dependent on the SUMOylation status of IGF-1R.
Based on the present and previous findings, we hypothesize that SUMO-dependent IGF-1R-induced gene activation may explain the effects on cell proliferation. Accordingly, the remaining step is to identify the specific genes involved in this context. For this purpose, our model system, R-WT versus. R-TSM, may be helpful. Applying expression microarray or RNA sequencing, it should be possible to identify genes whose expression differs between R-WT and R-TSM.
Some of these genes may, for example, control and coordinate expression of cell cycle proteins (like cyclin D1, A, and CDK2), but apart from genes regulating cell proliferation the model system may also identify SUMO-IGF-1R dependent gene expressions connected to other cellular functions (like apoptosis and cellular migration). Figure 6 briefly summarizes our hypothesis.
